For this purpose, T47D (BC cell line, BRCA1 and BRCA2 wt., HRP) and HeLa cells (cervical cancer cell line, BRCA1 and BRCA2 wt., HRP) were treated with a combination of curcumin (10, 20, and 30 μM) and the PARPi olaparib (0.1 and 0.25 μM). This evidence concerns the gene BRCA2 and cervical cancer.